IL6 and mantle cell lymphoma: In addition, since lenalidomide can inhibit IL-6 production, it could potentially inhibit the pro-survival activity of bone marrow-derived stromal cells in MCL via subsequent inhibition of IL-6- mediated STAT-3 signalling [91].